Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A-synuclein is aggregated and accumulated in neurons and glia in PD and considered the pathogenic culprit of the disease.
|
31812666 |
2020 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rats and mice with unilateral damage to the nigrostriatal dopamine system-induced by neurotoxins, such as 6-hydroxydopamine, overexpression of α-synuclein, or injections of toxic synuclein protofibrils-are widely used as experimental models to mimic the loss of dopamine neurons seen in Parkinson's disease.
|
30741691 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The etiology of Parkinson's disease (PD) is linked with cellular inclusions in the <i>substantia nigra pars compacta</i> region of the brain that are enriched in the misfolded presynaptic protein <i>α</i>-synuclein (<i>α</i>S) and death of the dopaminergic neurons.
|
31687080 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>α</i>-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease.
|
31211166 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that treatment with 7,8-DHF improved PD model's behavioral performance and reduced dopaminergic neuron loss in the SN and striatum, associated with the activation of TrkB receptors and its signaling cascades, and reduced <i>p</i>-MAPK, <i>p</i>-<i>α</i>-synuclein, and <i>p</i>-tau.
|
30944722 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We are witnessing exciting times, with the first clinical trials being conducted that target synuclein, and bring the hope of novel therapies for patients with PD and their families.
|
31441047 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulation of <alpha>-synuclein (<alpha>-syn) positive protein aggregates in the substantia nigra is a pathological hallmark of PD, indicating that protein turnover defect is implicated in PD pathogenesis.
|
31048127 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tyrosine hydroxylase (TH) was increased significantly and <i>α</i>-synuclein protein expression was reduced in the EX-PD group compared to the SED-PD group.
|
31309116 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study suggests that chronic intermittent hypoxia can increase the <i>α</i>-synuclein levels, which may contribute to the pathogenesis of Parkinson's disease.
|
31020003 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Removing or preventing the formation of [Formula: see text]-synuclein aggregates is a plausible strategy against Parkinson's disease.
|
31389332 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, this review discusses the events of cross presentation of synuclein peptides by professional antigen presenting cells and microglia, induction of inflammatory responses in the periphery and brain, and emerging calpain-targeted therapeutic strategies to attenuate neuronal death in PD.
|
31601400 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence suggests that various forms of <i>α</i>-synuclein- (<i>α</i>Syn-) mediated microglial activation are associated with the progression of Parkinson's disease.
|
31182996 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, Synuclein A, a key molecule in Parkinson's disease, was upregulated in the subgroup of glucocorticoid-sensitive subjects.
|
31091335 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNAs: Game Changers in the Regulation of <i>α</i>-Synuclein in Parkinson's Disease.
|
31191899 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune alterations in response to extracellular <i>α</i>-synuclein may play a critical role in modulating Parkinson's disease progression.
|
29850629 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The synuclein family is composed of three members, two of which, α- and β-synuclein, play a major role in the development of synucleinopathies, including Parkinson's disease (PD) as most important movement disorder, dementia with Lewy bodies (DLB) as the second most frequent cause of dementia after Alzheimer's disease and multiple system atrophy.
|
29370097 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, epigenetic alterations of the gene encoding for <i>α</i>-synuclein (<i>SNCA</i>) have been widely explored in both brain and peripheral tissues of Parkinson's disease samples.
|
29849887 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The intrinsically disordered protein β-synuclein is known to inhibit the aggregation of its intrinsically disordered homolog, α-synuclein, which is implicated in Parkinson's disease.
|
29782835 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plant Extracts and Phytochemicals Targeting <i>α</i>-Synuclein Aggregation in Parkinson's Disease Models.
|
30941047 |
2018 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study aims to investigate whether Long non-coding RNA (LncRNA)-UCA1 can regulate the progression of Parkinson's disease (PD) by mediating a-synuclein (SNCA) expression.
|
30536337 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synuclein, a component of LBs, is the defining characteristic of Parkinson's disease (PD).
|
29434298 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We go on to discuss the links between CMA and PD including CMA's role in ɑ-synuclein processing, oxidative stress, and mitochondrial function.
|
30185079 |
2018 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, our study showed that different SNCA and SNCB genotypes are associated with the development of either PD or DLB, and that the frequencies of genotypes associated with low SNCB expression are elevated in DLB.
|
30040713 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-486-3p Influences the Neurotoxicity of a-Synuclein by Targeting the SIRT2 Gene and the Polymorphisms at Target Sites Contributing to Parkinson's Disease.
|
30562735 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of RBD in PD is associated with faster motor progression in patients with greater synuclein and dopaminergic pathology, and with higher risk of cognitive decline in patients with greater synuclein and amyloid pathology.
|
30089615 |
2018 |